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Available online xxxxAim and Background: Dipyridamole-induced stress myocardial perfusion scans (MPS) has been widely used for
management of coronary artery disease. The adverse effects of dipyridamole and other stress agents have been
evaluated. The aim of this research is to conﬁrm the dynamic data on dipyridamole side effects during MPS.
Methods:We collected data of 183 patients who underwent dipyridamole-induced stressMPS by retrospectively
reviewing their clinical records, which included the severity of dipyridamole side effects in 3 min, 10 min, and
20 min after infusion. The incidence and severity at all three points, including the effect of age and gender,
were obtained.
Results: Adverse effects occurred in 96 patients (69.6%). The most frequent symptoms were dizziness (42.8%),
chest tightness (24.6%), abdominal pain (18.1%), and headache (15.2%). Most symptoms were Grade 1 to 2, ac-
cording to the grading system for common terminology criteria. The median duration of symptom persistence
was 36 min, not signiﬁcantly different among age and gender.
Conclusion: This study demonstrates that the adverse effects of dipyridamolewere generallyminimal and its du-
ration was acceptable for clinical usage.
© 2016 The Author(s). Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Adverse effects1. Introduction
Cardiovascular disease has been the secondmost commonmortality
since 2000 in Taiwan [1].Myocardial perfusion imaging (MPI) is a useful
tool in diagnosing and followup care for coronary artery disease [2]. Ac-
cording to current clinical guidelines for better sensitivity and speciﬁci-
ty, the exam is performed with a stress test [2–4]. Dipyrdamole, a
vasodilator, is one of the most widely used agents in stress tests in
Taiwan. According to prior literature, up to 70% of patients undergoing
dipyridamole stress suffer from adverse effects such as ﬂush, chest
pain, headache, dizziness, hypotension, abdominal pain, or diarrhea
[5–9]. However, severity and duration of adverse effects have not been
analyzed. As stated, the aim of this study is to examine dynamic data
of dipyridamole side effects during MPS.v.tw (S.-D. Lee).
reland Ltd. This is an open access arti2. Materials and methods
2.1. Patients and data collection
In our institute, symptoms of patients receiving dipyridamole-stress
MPI for 3min, 10min, and 20minwere recorded, according to the Com-
mon Terminology Criteria of Adverse Effects v4.0 (CTCAE) [10]. Records
were written andmaintained by physicians and technicians. Symptoms
recorded included: chest tightness, palpitation, abdominal pain, diar-
rhea, nausea, headache, dizziness, neck pain, dyspnea, weakness, and
ﬂush. If symptoms persisted for more than 20 min after administration,
we recorded timing of recovery. In the case of aminophylline use to re-
lieve adverse effects, we also recorded administration timing.
From July 2nd 2013 to July 19th 2013, there were 183 patients re-
ceiving MPI. There were 138 complete records of symptoms after deliv-
ery of dipyridamole. For an evaluation of confounding factors, we
collected the following parameters: age, gender, and frequency of regu-
lar exercise. These comorbidities were recorded in the clinical chart re-
view: hypertension, diabetes, dyslipidemia, prior myocardial infarction
(MI), documented coronary artery disease (CAD), and congestivecle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 2
Number and percentage of symptoms at 3, 10, and 20 min.
3rd minute 10th minute 20th minute Any time
Chest tightness 26 (18.8%) 24 (17.4%) 17 (12.3%) 34 (24.6%)
Palpitation 4 (2.9%) 2 (1.4%) 2 (1.4%) 5 (3.6%)
Abdominal pain 13 (9.4%) 19 (13.8%) 7 (5.1%) 25 (18.1%)
Dyspnea 10 (7.3%) 7 (5.1%) 4 (2.9%) 12 (8.7%)
Diarrhea 0 0 0 0
Nausea 5 (3.6%) 7 (5.1%) 7 (5.1%) 11 (8.0%)
Headache 16 (11.6%) 13 (9.4%) 11 (8.0%) 21 (15.2%)
Dizziness 52 (37.7%) 45 (32.6%) 30 (21.7%) 59 (42.8%)
Neck pain 5 (3.6%) 5 (3.6%) 8 (5.8%) 10 (7.2%)
Weakness 3 (2.2%) 6 (4.3%) 7 (5.1%) 7 (5.1%)
Flush 3 (2.2%) 1 (0.7%) 1 (0.7%) 4 (2.9%)
Overall 84(60.9%) 79 (57.2%) 56 (40.6%) 96 (69.6%)
15S.-D. Lee et al. / IJC Heart & Vasculature 14 (2017) 14–19heart failure. The laboratory data over 3 months were also recorded:
creatinine level, lipid proﬁle, and hepatic enzyme glutamate pyruvate
transaminase (GPT).
These methods were approved by our institutional review board.
2.2. Stress protocol
All patients underwent the Thallium-201 (Tl-201) stress and early-
redistributionMPI with the dipyridamole stress test, on the recommen-
dation of the Society of Nuclear Medicine and Molecular Imaging
(SNMMI and EANM). Heart rate, blood pressure, and ECG monitoring
were performed throughout the stress test.
2.3. Statistics
R project version 3.1.2 was used for statistical analysis. The continu-
ous parameters were expressed in terms of mean and standard
deviation (SD). The categorical variables were expressed as count and
percentage. Severity of each symptom at 3 min, 10 min, and 20 min
were also expressed as count and percentage.
The Kaplan-Meier curvewas used to highlight persistent symptoms.
Patients were in two groups according to age (age N65). For an eval-
uation of confounding factors, e.g., gender and age, the Kaplan-Meier
curve and Cox regression test were used for comparison between
males and females, the age groups, and the exercise groups.
3. Results
Data from 138 patients were analyzed and listed in Table 1. The av-
erage agewas 66.1± 13.4 years (range 32–90). Seventy-ﬁveweremale
(54.3%) and 60 study subjects exercised more than 3 times per week
(43.5%). There were 96 patients (69.6%) suffering from symptoms of
drug side effects during observation. Between the symptomatic and
asymptomatic group, the incidence of comorbidities and lab data were
not statistically different, except that the serum creatinine level wasTable 1
Patient background information.
Total Sympto
Number 138 96
Gender
Male 75 (54.3%) 41 (42.7
Female 63 (45.7%) 55 (57.3
Age (years old) 66.1 ± 13.4 (32-90) 64.2 ±
Frequency of exercise
(times per week)
Range 0-7
Median 1
Mean 2.8 2.9
≥3 60 (43.5%)
Using aminophylline 18
Timing (min) 22.2 ± 8.5
Comorbidity
Hypertension 85 (61.6%) 56 (58.3
Diabetes 37 (26.8%) 24 (25.0
Dyslipidemia 51 (37.0%) 34 (35.4
Prior MI 22 (15.9%) 14 (14.6
Documented CAD 39 (28.3%) 23 (24.0
Congestive heart failure 10 (7.2%) 7 (7.3%)
Creatinine (n = 125) 1.37 ± 1.07 (0.57–6.87) 1.19 ±
HDL (n = 111) 40.31 ± 10.52 (19–77) 40.83 ±
LDL (n = 111) 97.52 ± 29.16 (41–218) 97.17 ±
TG (n = 106) 155.95 ± 113.54 (35–769) 162.07
GPT (n = 119) 29.77 ± 26.98 (4–261) 29.66 ±
Pretest SBP 150.95 ± 22 (101–214) 150.25
Pretest DBP 86.88 ± 12.3 (57–126) 86.87 ±
Post test SBP 130.8 ± 18.27 (94–188) 132.02
Post test DBP 75.21 ± 11.87 (49–113) 75.8 ±higher in the asymtomatic group. However, in the symptomatic group,
the ratio of female patients was signiﬁcantly higher than in the asymp-
tomatic group (p=0.002141), while the age was signiﬁcantly younger
(p= 0.009262).
The frequency and severity of adverse effects are listed in Table 2 and
Fig. 1. Adverse effects occurred in 96patients (69.6%),with themost fre-
quent symptoms being dizziness (42.8%), chest tightness (24.6%), ab-
dominal pain (18.1%), and headache (15.2%). These effects accompany
dyspnea (8.7%), nausea (8.0%), neck pain (7.2%), weakness (5.1%), pal-
pitation (3.6%), and ﬂush (2.9%). No patients had diarrhea in our study
population, while most symptoms were Grade 1 and 2. Seven patients
had Grade 3 symptoms as shown in Table 6. There were 18 patients re-
ceiving aminophylline treatment due to adverse effects. For patients
with symptoms at 3 min, the persistent symptoms can be seen in the
Kaplan-Meier curve (Fig. 2). The median duration of persistent symp-
toms was 36 min (95% conﬁdence interval [CI]: 30–46 min). Fifty-six
patients (40.6%) did not recover from side effects at 20 min, while 32
of them were female.matic Asymptomatic P-value
42
0.002141
%) 33 (78.6%)
%) 9 (21.4%)
13.24 (32-90) 70.6 ± 12.88 (41-90) 0.009262
2.5 0.4626
%) 29 (69.0%) 0.317
%) 13 (31.0%) 0.6048
%) 17 (40.5%) 0.7077
%) 8 (19.0%) 0.6844
%) 16 (38.1%) 0.1358
3 (7.1%) 1
0.77 (0.57–6.69) 1.79 ± 1.49 (0.81–6.06) 0.02368
10.83 (22–77) 39.17 ± 9.88 (19–59) 0.4284
27.07 (41–195) 98.29 ± 33.69 (48–218) 0.8642
± 108.49 (42–69) 142.42 ± 124.68 (35–552) 0.438
17.7 (6–101) 30.03 ± 41.48 (4–261) 0.9597
± 23.32 (101–214) 152.57 ± 18.82 (110–183) 0.5392
13.43 (57–126) 86.90 ± 9.40 (71–106) 0.9876
± 19.37 (94–188) 128.02 ± 15.29 (94–164) 0.1971
12.37 (52–113) 73.86 ± 110.65 (49–95) 0.3505
Fig. 1. Severity of adverse effects after dipyridamole infusion at 3 different points. Grading is based on CTCAE v4.0.
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the female population than the male population at all points (Tables 1
and 3). There is a higher incidence in women for the three time points
of dizziness, chest tightness, abdominal pain, headache, dyspnea, nau-
sea,weakness, and palpitation.However, there is a signiﬁcant difference
between genders for dizziness only at 10 min.
There is no signiﬁcant difference of symptom duration between
genders (Fig. 3), as the p value of the Cox regression is 0.421. The
median time for symptom-relief took 33 min for women and 36 min
for men. Women tend to have a higher incidence of adverse effects,
andmore severe symptoms. There is a signiﬁcant difference in dizziness
between the two groups at 10 min (p= 0.003724).
Younger patients (age b65) tended to have a higher probability of
adverse effects than older patients, which was the only statistically sig-
niﬁcant difference at 3 min (Table 4). The younger group had a greater
risk for all symptoms except dizziness. Symptom duration was similarFig. 2. For patients with symptoms at 3 min, persistence is shown in the Kaplan-Meier
curve.between age groups (Fig. 4), and p = 0.374. The median time of
symptom-relief took 33min in older people and 48min in younger peo-
ple. Younger people also had a higher incidence of adverse effects and
more severe symptoms. There was not a signiﬁcant difference for
chest tightness and nausea between the two groups at 3 min (p =
0.000162). Exercise did not interfere with adverse dipyridamole effects
in our study. (See Table 5.)4. Discussion
The purpose of the MPI stress test is to induce a distinction in blood
ﬂow between normal coronary arteries and those with stenosis.
Dipyridamole has been used as a pharmaceutical method of stress
testing. Dipyridamole infusion blocks reabsorption and metabolism
of endogenic adenosine [11,12], elevates extra-cellular adenosine
concentration [12,13], non-selectively activates all types of adenosine
receptors [12], induces vascular resistance of normal coronary artery
decrease, and creates myocardial blood ﬂow increase up to 5-fold
[11–13]. On the other hand, the blood ﬂow of the myocardium, which
is supplied by stenosed coronary arteries, was unable to increase
blood ﬂow from the stress due to compensatory dilation at rest [11,
12]. Dipyridamole-stress MPI is able to detect coronary artery disease
as accurately as exercise stress tests, and provides prognostic informa-
tion regarding cardiac death and myocardial infarction [11].
Using dipyridamole in myocardial perfusion is generally safe [5–8,
13,14]. Nevertheless, up to 70% of patients undergoing dipyridamole
stress suffer from variable adverse effects, such as ﬂush, chest pain,
headache, dizziness, hypotension, abdominal pain, or diarrhea [5–9].
Adverse effects can develop from stimulating different types of adeno-
sine receptors and signal pathways, including peripheral vasodilation
and hypotension [12].
In our study population, 69.6% of patients suffered from the adverse
effects of dipyridamole. The most frequent symptoms were dizziness,
chest tightness, abdominal pain, and headache. Prior literature shows
the incidence of adverse effects from dipyridamole can range from
27.9% to 75.36% [5–7,9,15–17]. However, there is a wide variation of
the deﬁnition of adverse effects among studies.
Fig. 3. For patients with symptoms at 3 min, persistence is shown in the Kaplan-Meier
curve. There is no difference between genders.
Table 4
Incidence of symptomatic patients at 3, 10, and 20 min for age.
Age b 65
(n = 63)
Age ≥ 65
(n = 75)
p value
3rd minute 46 (73.0%) 38 (50.7%) 0.01226⁎
Chest tightness 21 (33.3%) 5 (6.7%) 0.000162⁎
Palpitation 3 (4.8%) 1 (1.3%) 0.4924
Abdominal pain 8 (12.7%) 5 (6.7%) 0.3598
Dyspnea 6 (9.5%) 4 (5.3%) 0.5378
Diarrhea 0 0 –
Nausea 5 (7.9%) 0 0.04257⁎
Headache 11 (17.5%) 5 (6.7%) 0.08804
Dizziness 22 (34.9%) 29 (38.7%) 0.7817
Neck pain 4 (6.3%) 1 (1.3%) 0.2656
Weakness 2 (3.2%) 1 (1.3%) 0.8785
Flush 2 (3.2%) 1 (1.3%) 0.8785
10th minute 41 (65.1%) 37 (49.3%) 0.09175
Chest tightness 15 (23.8%) 9 (12.0%) 0.1101
Palpitation 1 (1.6%) 1 (1.3%) 1
Abdominal pain 10 (15.9%) 9 (12.0%) 0.682
Dyspnea 4 (6.3%) 3 (4.0%) 0.8126
Diarrhea 0 0 –
Nausea 6 (9.5%) 1 (1.3%) 0.07271
Headache 9 (14.3%) 4 (5.3%) 0.1334
Dizziness 21 (33.3%) 24 (32.0%) 1
Neck pain 4 (6.3%) 1 (1.3%) 0.2656
Weakness 4 (6.3%) 2 (2.7%) 0.5237
Flush 1 (1.6%) 0 0.9302
20th minute 30 (47.6%) 26 (34.7%) 0.1709
Chest tightness 11 (17.5%) 6 (8.9%) 0.1543
Palpitation 1 (1.6%) 1 (1.3%) 1
Abdominal pain 2 (3.2%) 5 (6.7%) 0.588
Dyspnea 2 (3.2%) 2 (2.7%) 1
Diarrhea 0 0 –
Nausea 5 (7.9%) 2 (2.7%) 0.3097
Headache 8 (12.7%) 3 (4.0%) 0.1179
Dizziness 13 (20.6%) 17 (22.7%) 0.9354
Neck pain 4 (6.3%) 4 (5.3%) 1
Weakness 4 (6.3%) 3 (4.0%) 0.8126
Flush 1 (1.6%) 0 0.9302
Any time 47 (74.6%) 49 (65.3%) 0.3206
Chest tightness 22 (34.9%) 12 (16.0%) 0.01774⁎
Palpitation 4 (6.3%) 1 (1.3%) 0.2656
Abdominal pain 12 (19.0%) 13 (17.3%) 0.9692
Dyspnea 8 (12.7%) 4 (5.3%) 0.2201
Diarrhea 0 0 –
Nausea 9 (14.3%) 2 (2.7%) 0.2818
Headache 13 (20.6%) 8 (10.7%) 0.1657
Dizziness 24 (38.1%) 35 (46.7%) 0.4003
Neck pain 5 (7.9%) 5 (6.7%) 1
Weakness 4 (6.3%) 3 (4.0%) 0.8126
Flush 3 (4.8%) 1 (1.3%) 0.4924
Table 3
Incidence of symptomatic patients at 3, 10, and 20 min for gender.
Male (n = 75) Female (n = 63) p value
3rd minute 35 (46.7%) 49 (77.8%) 0.000378⁎
Chest tightness 10 (13.3%) 16 (25.4%) 0.1126
Palpitation 1 (1.3%) 3 (4.8%) 0.4924
Abdominal pain 6 (8.0%) 7 (11.1%) 0.7409
Dyspnea 3 (4.0%) 7 (11.1%) 0.2022
Diarrhea 0 0 –
Nausea 1 (1.3%) 4 (6.3%) 0.2656
Headache 7 (9.3%) 9 (14.3%) 0.5233
Dizziness 24 (32.0%) 27 (42.9%) 0.2546
Neck pain 1 (1.3%) 4 (6.3%) 0.2659
Weakness 0 3 (4.8%) 0.1853
Flush 2 (2.7%) 1 (1.6%) 1
10th minute 32 (42.7%) 46 (73.0%) 0.0006497⁎
Chest tightness 10 (13.3%) 14 (22.2%) 0.2515
Palpitation 1 (1.3%) 1 (1.6%) 1
Abdominal pain 8 (10.7%) 11 (17.5%) 0.3651
Dyspnea 1 (1.3%) 6 (9.5%) 0.07271
Diarrhea 0 0 –
Nausea 2 (2.7%) 5 (7.9%) 0.3097
Headache 6 (8.0%) 7 (11.1%) 0.7409
Dizziness 16 (21.3%) 29 (46.0%) 0.003724⁎
Neck pain 3 (4.0%) 2 (3.2%) 1
Weakness 1 (1.3%) 5 (7.9%) 0.14
Flush 1 (1.3%) 0 1
20th minute 24 (32.0%) 32 (50.8%) 0.03888⁎
Chest tightness 7 (9.3%) 10 (15.9%) 0.3658
Palpitation 1 (1.3%) 1 (1.6%) 1
Abdominal pain 1 (1.3%) 6 (9.5%) 0.07271
Dyspnea 1 (1.3%) 3 (4.8%) 0.4924
Diarrhea 0 0 –
Nausea 2 (2.7%) 5 (7.9%) 0.3097
Headache 5 (6.7%) 6 (9.5%) 0.7628
Dizziness 12 (16.0%) 18 (28.8%) 0.115
Neck pain 4 (5.3%) 4 (6.3%) 1
Weakness 2 (2.7%) 5 (7.9%) 0.3097
Flush 0 1 (1.6%) 0.9302
Any time 42 (56.0%) 54 (85.7%) 0.0003269⁎
Chest tightness 14 (18.7%) 20 (31.7%) 0.1146
Palpitation 2 (2.7%) 3 (4.8%) 0.8424
Abdominal pain 11 (14.7%) 14 (22.2%) 0.3544
Dyspnea 3 (4.0%) 9 (14.3%) 0.06684
Diarrhea 0 0 –
Nausea 3 (4.0%) 8 (12.7%) 0.1179
Headache 8 (10.7%) 13 (20.6%) 0.1657
Dizziness 25 (33.3%) 34 (54.0%) 0.02333⁎
Neck pain 4 (5.3%) 6 (9.5%) 0.5378
Weakness 2 (2.7%) 5 (7.9%) 0.3097
Flush 2 (2.7%) 2 (3.2%) 1
17S.-D. Lee et al. / IJC Heart & Vasculature 14 (2017) 14–19Thehalf-life of dipyridamole is approximately 30–45min [12]. In our
study, the median duration of persistent symptoms was 36 min. Dura-
tion of symptoms was not signiﬁcantly different between gender and
age group.
In our study population, the most frequent symptom was dizziness,
which made up 42.8% of patients. Most of the symptoms were Grade 1,
although nobody suffered from severe dizziness (Grade 3). A study by
Takeishi et al. revealed similar results, i.e., that the incidence of dizziness
from dypiridamole-stress MPI was 51% [17]. In contrast, Colarinha et al.
showed that 13 individuals out of 140 patients (9.3%) undergoingTable 5
Number and percentage of symptomatic patients at 3, 10, and 20min in two different life-
style groups.
Weekly exercise b3 times Weekly exercise N3 times p value
3rd minute 47 (60.3%) 37 (61.7%) 1
10th minute 44 (56.4%) 34 (56.7%) 1
20th minute 33 (42.3%) 23 (38.3%) 0.7669
Any time 53 (67.9%) 43 (71.7%) 0.7764
Table 6
List of patients with Grade 3 symptoms.
# Gender Age Major symptoms Associated symptoms Treatment Timing of resolution
1 M 60 Chest tightness Aminophylline at 13th minute 20th minute
6 F 70 Dyspnea Dizziness (grade 2) Aminophylline at 17th minute 20th minute
31 F 55 Chest tightness, abdominal pain Nausea after aminophylline (grade 3 at 20th minute) Aminophylline at 12th minute 20th minute
33 M 82 Chest tightness Aminophylline at 19th minute 20th minute
35 M 46 Weakness 26th minute
55 F 60 Chest tightness and headache Aminophylline at 18th minute 20th minute
74 F 63 Nausea Chest tightness (Grade 1), dizziness (grade 1) and ﬂush (Grade 2) Aminophylline at 25th minute 25th minute
Fig. 4. For patients with symptoms at 3 min, persistence is shown in the Kaplan-Meier
curve. There is no difference between genders.
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have resulted from different awareness levels of it.
The secondmost frequent symptomwas chest tightness, with an ac-
cumulated incidence of 24.6%. It is much higher than found in prior
studies, ranging from 0.68% to 16.4% [5,6,13,15,16], but lower than the
results of Takeishi et al [17]. Most of our patients suffered from mild
chest tightness, although only 12 patients (8.7%) had chest tightness
greater or equal to Grade 2, and only four people (2.9%) had Grade 3
chest tightness. Dipyridamole-induced chest tightness has been corre-
lated with more severe coronary artery disease [17].
According to our data, females have a greater potential to experience
adverse effects (Table 3 and Fig. 2). This phenomenon is revealed in a
prior study [6,8,18]. Our data revealed that women have a higher accu-
mulated risk for all symptoms. However, there is a statistically signiﬁ-
cant difference in dizziness at 10 min, similar to the results of Kong
et al. [18]. Prior reports show that adenosine-induced adverse effects
are higher in women [19–21]. The gender difference is not yet clear,
but could possibly be related to different fat-to-muscle ratio [18].
In our study population, younger subjects have greater potential to
have adverse effects, except for dizziness (Table 4). A report from
Lette et al. revealed that the frequency of dipyridamole-induced side ef-
fects is less in patients older than 70 [8]. Adenosine-related side effects
also occur more frequently in younger people [22]. Our data shows,
compared to those older than 65, that younger people have higher
risk of all symptoms, except dizziness. There is a signiﬁcant difference
of chest tightness and nausea between the two age groups, but only at
3 min.
The limitation of our study includes a retrospective study design
with some missing data (24.6%), and a relatively small population.
Due to these issues, we did not record symptom onset more than
20 min after the dipyridamole injection, and as such, any delayed ad-
verse effects were not evaluated.5. Conclusion
Our study reveals that dipyridamole use in MPS is generally safe.
Women and younger people tended to have a higher risk of adverse
effects. However, there is a trend that the elderly have a higher risk of
dizziness than younger people. Duration of adverse effects was not sig-
niﬁcantly different for gender and age.
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